{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:44:14Z","timestamp":1790397854024,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ghir.2017.03.001","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T23:06:49Z","timestamp":1490310409000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Low dose growth hormone treatment in infants and toddlers with Prader-Willi syndrome is comparable to higher dosage regimens"],"prefix":"10.1016","volume":"34","author":[{"given":"Elly","family":"Scheermeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Crock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Ambler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"Verge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Werther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.W.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ghir.2017.03.001_bb0005","author":"Department of Health, Pharmaceutical Benefits Scheme (PBS) Growth Hormone Program"},{"key":"10.1016\/j.ghir.2017.03.001_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","article-title":"Prader-Willi syndrome","volume":"14","author":"Cassidy","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ghir.2017.03.001_bb0015","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.earlhumdev.2006.09.002","article-title":"Clinical evidence of intrauterine disturbance in Prader-Willi syndrome, a genetically imprinted neurodevelopmental disorder","volume":"83","author":"Dudley","year":"2007","journal-title":"Early Hum. Dev."},{"key":"10.1016\/j.ghir.2017.03.001_bb0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.earlhumdev.2007.08.007","article-title":"Pre-, peri- and postnatal complications in Prader-Willi syndrome in a UK sample","volume":"84","author":"Whittington","year":"2008","journal-title":"Early Hum. Dev."},{"key":"10.1016\/j.ghir.2017.03.001_bb0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/ajmg.a.36405","article-title":"Hypoglycemia in Prader-Willi syndrome","volume":"164A","author":"Harrington","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ghir.2017.03.001_bb0030","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1210\/jc.2008-0649","article-title":"Recommendations for the diagnosis and management of Prader-Willi syndrome","volume":"93","author":"Goldstone","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.03.001_bb0035","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1067\/S0022-3476(03)00386-X","article-title":"Decreased energy expenditure is caused by abnormal body composition in infants with Prader-Willi syndrome","volume":"143","author":"Bekx","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ghir.2017.03.001_bb0040","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ajmg.a.33951","article-title":"Nutritional phases in Prader-Willi syndrome","volume":"155","author":"Miller","year":"2011","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ghir.2017.03.001_bb0045","series-title":"Prader-Willi Syndrome","first-page":"294","author":"Hoybye","year":"2013"},{"key":"10.1016\/j.ghir.2017.03.001_bb0050","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.neubiorev.2010.10.015","article-title":"Motor problems in Prader-Willi syndrome: a systematic review on body composition and neuromuscular functioning","volume":"35","author":"Reus","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ghir.2017.03.001_bb0055","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/jpc.12294","article-title":"Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis","volume":"49","author":"Scheermeyer","year":"2013","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.ghir.2017.03.001_bb0060","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jpeds.2004.08.002","article-title":"Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome","volume":"145","author":"Carrel","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ghir.2017.03.001_bb0065","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1365-2265.2007.03126.x","article-title":"Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome","volume":"68","author":"Festen","year":"2008","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2017.03.001_bb0070","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1352\/1944-7558-120.4.315","article-title":"Beneficial effects of long-term growth hormone treatment on adaptive functioning in infants With Prader-Willi syndrome","volume":"120","author":"Lo","year":"2015","journal-title":"Am. J. Intellect. Dev. Disabil."},{"key":"10.1016\/j.ghir.2017.03.001_bb0075","first-page":"753","article-title":"Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome","volume":"144","author":"Eiholzer","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ghir.2017.03.001_bb0080","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1515\/JPEM.2009.22.12.1151","article-title":"Benefit of early commencement of growth hormone therapy in children with Prader-Willi syndrome","volume":"22","author":"Nyunt","year":"2009","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.03.001_bb0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2265.2008.03228.x","article-title":"Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome","volume":"69","author":"Festen","year":"2008","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2017.03.001_bb0090","doi-asserted-by":"crossref","first-page":"E1516","DOI":"10.1210\/jc.2013-1831","article-title":"Growth hormone therapy and respiratory disorders: long-term follow-up in PWS children","volume":"98","author":"Berini","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.03.001_bb0095","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5664\/jcsm.27601","article-title":"Sleep disordered breathing in infants with Prader-Willi syndrome during the first 6 weeks of growth hormone therapy: a pilot study","volume":"5","author":"Miller","year":"2009","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.ghir.2017.03.001_bb0100","doi-asserted-by":"crossref","first-page":"E1072","DOI":"10.1210\/jc.2012-3888","article-title":"GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome","volume":"98","author":"Deal","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.03.001_bb0105","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1515\/jpem-2001-0805","article-title":"Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent","volume":"14","author":"Carrel","year":"2001","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.03.001_bb0110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/jpc.12109","article-title":"Are sleep studies helpful in children with Prader-Willi syndrome prior to commencement of growth hormone therapy?","volume":"49","author":"Vandeleur","year":"2013","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.ghir.2017.03.001_bb0115","author":"World Health Organization"},{"key":"10.1016\/j.ghir.2017.03.001_bb0120","author":"Centres for Disease Control and Prevention"},{"key":"10.1016\/j.ghir.2017.03.001_bb0125","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1651-2227.2000.tb00755.x","article-title":"Spontaneous growth in German children and adolescents with genetically confirmed Prader-Willi syndrome","volume":"89","author":"Hauffa","year":"2000","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ghir.2017.03.001_bb0130","first-page":"246","article-title":"2000 CDC Growth Charts for the United States: Methods and Development","volume":"11","author":"Kuczmarski","year":"2002"},{"key":"10.1016\/j.ghir.2017.03.001_bb0135","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1542\/peds.2010-2736","article-title":"Growth standards of infants with Prader-Willi syndrome","volume":"127","author":"Butler","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ghir.2017.03.001_bb0140","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.neubiorev.2012.05.005","article-title":"The effect of growth hormone treatment or physical training on motor performance in Prader-Willi syndrome: a systematic review","volume":"36","author":"Reus","year":"2012","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ghir.2017.03.001_bb0145","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1210\/jc.2013-2012","article-title":"Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects","volume":"98","author":"Bakker","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.03.001_bb0150","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jn\/137.1.144","article-title":"Comparison of the WHO child growth standards and the CDC 2000 growth charts","volume":"137","author":"de Onis","year":"2007","journal-title":"J. Nutr."},{"key":"10.1016\/j.ghir.2017.03.001_bb0155","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2147\/TCRM.S70068","article-title":"Growth hormone therapy for Prader-willi syndrome: challenges and solutions","volume":"12","author":"Grugni","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ghir.2017.03.001_bb0160","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40618-015-0312-9","article-title":"Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings","volume":"38","author":"Angulo","year":"2015","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.ghir.2017.03.001_bb0165","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1210\/jc.2009-1831","article-title":"Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment","volume":"95","author":"Feigerlova","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.03.001_bb0170","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1210\/jc.2015-1410","article-title":"IGF-1 levels, complex formation, and IGF bioactivity in growth hormone-treated children with Prader-Willi syndrome","volume":"100","author":"Bakker","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.03.001_bb0175","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/cen.12315","article-title":"Comparison of weight- vs body surface area-based growth hormone dosing for children: implications for response","volume":"80","author":"Hughes","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2017.03.001_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101012","article-title":"Clinically important age-related differences in sleep related disordered breathing in infants and children with Prader-Willi syndrome","volume":"9","author":"Cohen","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ghir.2017.03.001_bb0185","series-title":"IPWSO 8th International PWS Scientific Conference. Cambridge, UK","article-title":"Prevalence of spinal deformities in Prader-Willi syndrome","author":"van Bosse","year":"2013"},{"key":"10.1016\/j.ghir.2017.03.001_bb0190","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.ridd.2012.12.015","article-title":"Objective evaluation of muscle strength in infants with hypotonia and muscle weakness","volume":"34","author":"Reus","year":"2013","journal-title":"Res. Dev. Disabil."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637417300308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637417300308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:49:34Z","timestamp":1761086974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637417300308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":38,"alternative-id":["S1096637417300308"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2017.03.001","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low dose growth hormone treatment in infants and toddlers with Prader-Willi syndrome is comparable to higher dosage regimens","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2017.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}